The efficacy and safety of DUPIXENT was evaluated for up to 52 weeks in two multipart, phase 3 clinical trials.
ADULTS & ADOLESCENTS AGED 12+ YEARS
Study design: Part A and Part B each consisted of a 24-week double-blind treatment period. Subjects who completed Part A or Part B were then eligible to enroll in a 28-week extended active treatment period (Part A-C or Part B-C, respectively) totaling 52 weeks of treatment.1,3,4
Overview: A total of 188 subjects aged 12+ years were enrolled in the extended active treatment period (77 in Part A-C and 111 in Part B-C). Management of the disease was evaluated through clinical, histologic, and endoscopic endpoints.1,3
CHILDREN AGED 1-11 YEARS
Study design: EoE KIDS-Part A consisted of a 16-week double-blind treatment period. Subjects who completed Part A were then eligible to enroll in a 36-week extended active treatment period (EoE KIDS-Part B) totaling 52 weeks of treatment.1
Overview: A total of 47 subjects aged 1-11 years were enrolled in the extended active treatment period. Management of the disease was evaluated through clinical, histologic, and endoscopic endpoints.1